Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics Inc (IKT) is a clinical-stage pharmaceutical company pioneering protein kinase inhibitors for neurodegenerative disorders, including Parkinson's disease. This page serves as the definitive source for official announcements, clinical trial updates, and strategic developments from the company.
Investors and researchers will find curated updates on drug pipeline progress, regulatory milestones, and scientific advancements. Our collection includes earnings reports, partnership announcements, preclinical study results, and FDA correspondence related to candidates like Risvodetinib (IkT-148009) and IkT-001Pro.
All content is rigorously verified to ensure compliance with financial disclosure standards. Bookmark this page for real-time updates on:
• Clinical trial phases for Parkinson's-focused therapies
• Regulatory filings and agency interactions
• Peer-reviewed research publications
• Strategic collaborations in neurodegenerative research
For stakeholders tracking kinase inhibitor development and neurodegenerative treatment innovation, this resource provides essential updates directly from Inhibikase Therapeutics' corporate communications.
Inhibikase Therapeutics, Inc. (IKT) has announced the dosing of the first patient in its Phase 2a '201 trial' for IkT-148009, a c-Abl inhibitor aimed at treating Parkinson's disease. This trial involves 120 untreated patients and will evaluate safety, tolerability, and pharmacokinetics over 12 weeks. Preliminary animal studies suggested functional recovery could occur within eight weeks. The company anticipates increased patient enrollment as more trial sites become operational, highlighting its commitment to improving the lives of those affected by neurodegenerative diseases.
Inhibikase Therapeutics (Nasdaq: IKT) reported a net loss of $4.6 million, or $0.18 per share, for Q2 2022, compared to a net loss of $2.6 million, or $0.22 per share, in Q2 2021. R&D expenses increased by $0.6 million to $3.0 million, driven by clinical trial costs. The company has opened enrollment for its Phase 2a trial of IkT-148009 for Parkinson's disease and filed an IND application for IkT-001Pro for chronic myelogenous leukemia. As of June 30, 2022, Inhibikase had $32.2 million in cash, sufficient to fund operations through December 2023.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced it will release its financial results for Q2 2022 on August 12, 2022. The company will follow up with a conference call on August 15, 2022, at 8:00 a.m. ET to discuss the results and provide a corporate update. Inhibikase specializes in developing therapeutics for Parkinson's disease and related disorders, focusing on its lead program, IkT-148009, a c-Abl inhibitor.
Inhibikase Therapeutics (Nasdaq: IKT) has announced the advancement of its Phase 2a study ('201 trial') for IkT-148009 after favorable results from the Phase 1/1b ('101 trial'). The 101 trial, which evaluated dosing in Parkinson's patients, demonstrated a positive safety and tolerability profile. The FDA has granted approval to proceed with the 201 trial, expecting to dose the first patient by 2Q 2022. The upcoming trial will focus on long-term safety and efficacy in untreated Parkinson’s patients, marking a significant step in addressing unmet needs in Parkinson's disease treatment.
Inhibikase Therapeutics (Nasdaq: IKT) reported its Q1 2022 financial results, revealing a net loss of $4.7 million, or $0.18 per share, up from a loss of $2.6 million, or $0.26 per share, in Q1 2021. R&D expenses rose to $3.0 million, primarily due to Phase I clinical trial expenditures. Cash and cash equivalents were $36.6 million, sufficient to fund operations into Q3 2023. The company anticipates initiating its Phase 2a study for IkT-148009 in Parkinson's disease and submitting an IND for IkT-001Pro for Chronic Myelogenous Leukemia this quarter.
On May 10, 2022, Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner, President & CEO, will present at the H.C. Wainwright Global Investment Conference in Miami Beach, FL, scheduled for May 25, 2022 at 2:30 pm ET. The company is focused on developing therapies for Parkinson's disease and related disorders, with a lead program targeting the treatment of neurodegeneration. Inhibikase's multi-therapeutic pipeline includes IkT-148009 and other drug delivery technologies, aimed at enhancing patient experience.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) will report its first-quarter 2022 financial results on May 16, 2022, after U.S. market close. A conference call will follow on May 17, 2022, at 8:00 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing therapeutics for Parkinson's disease and related disorders, with its lead program targeting neurodegeneration. Investors can access the call through specified phone numbers or via a live webcast.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced Dr. Milton Werner will participate in a fireside chat at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 2:30 PM ET. A live webcast will be available for on-demand viewing on the company's website, with an archival replay accessible for 30 days. The company focuses on developing therapeutics for Parkinson's disease, notably its lead program IkT-148009, aimed at treating the disease both in the brain and gastrointestinal tract.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) will host a virtual KOL investor event on April 20, 2022, at 10:00 am ET. The event will feature presentations from the executive leadership team and key opinion leaders, including Dr. Robert F. Hauser and Dr. Werner Poewe. They will discuss data from Phase 1 and 1b studies of IkT-148009, the company's lead candidate for Parkinson's disease treatment, and outline the upcoming Phase 2 program. A live webcast will be available on the company’s website, with a replay accessible for 90 days.
Inhibikase Therapeutics (Nasdaq: IKT) reported its 2021 financial results, noting a net loss of $14.8 million, or $0.81 per share, compared to $2.8 million, or $0.35 per share, in 2020. Grant revenue surged to $3.1 million from $0.7 million, driven by increased research activity. The company emphasized the successful advancement of its lead program, IkT-148009, into clinical trials for Parkinson's disease. The Phase 1b study showed a favorable safety profile, and a Phase 2a trial is anticipated to start in Q2 2022. Cash reserves stood at $40.8 million, sufficient until Q3 2023.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
